Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734656 · ClinicalTrials.gov registry record · NA
Pharmacogenetics of Alcohol: Treatment Implications
A NA study, sponsored by UConn Health.
- Completed
- Registry status
- NA
- Development phase
- 94
- Enrollment target
NCT00734656: Completed NA study, sponsored by UConn Health.
NCT00734656 is a NA study that has completed, run by UConn Health. The registered enrollment target is 94 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734656, a NA study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 94 participants
- Enrollment target
Study Summary
This study will explore the hypothesis that effects of alcohol are in part mediated by increased production of neuroactive steroids, which interact with GABAA-receptors. We propose to study non-dependent drinkers using a 4-session within-subjects design in which alcohol / placebo is paired with dutasteride / placebo pretreatment. Dutasteride is a 5-alpha steroid reductase (5AR) inhibitor that limits the production of dihydrotestosterone and the 5a-reduced neuroactive steroids allopregnanolone, pregnanolone and 3a,5a-androstanediol.
Primary Outcome
Breath Alcohol level
Interventions
- DRUG dutasteride + ethanol
- DRUG placebo medication + ethanol
- DRUG dutasteride + placebo alcohol
- DRUG placebo medication + placebo alcohol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-07 |
| Phase | NA |
What the finished NCT00734656 record still lists
NCT00734656 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which dutasteride + ethanol is the first listed.
NCT00734656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00734656 about?
NCT00734656 is a clinical study titled "Pharmacogenetics of Alcohol: Treatment Implications". This study will explore the hypothesis that effects of alcohol are in part mediated by increased production of neuroactive steroids, which interact with GABAA-receptors. We propose to study non-dependent drinkers using a 4-session within-subjects design in which alcohol / placebo is paired with duta...
What is the current status of trial NCT00734656?
This trial is currently completed. It is a NA study. The enrollment target is 94 participants. The study started on 2007-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00734656?
The interventions under investigation include: dutasteride + ethanol (DRUG), placebo medication + ethanol (DRUG), dutasteride + placebo alcohol (DRUG), placebo medication + placebo alcohol (DRUG).
Who is sponsoring clinical trial NCT00734656?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00734656's enrollment target sits among peer trials
94 935th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia